Aethlon Medical, Inc. · NASDAQ:AEMD
Aethlon Medical — Investor Presentation (June 2026)
21 slides from Aethlon Medical's investor presentation, June 2026
Slide 1: The Hemopurifier Platform
NASDAQ: AEMD The Hemopurifi er® Platform Targeting Cancer, Viral Threats, and Transplant June 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This investor presentation contains forward-looking statements, as that term is defi ned in the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
Slide 3: Investment Highlights
Investment Highlights • Patented Hemopurifi er® platform blood Early clinical data demonstrating clearance of enveloped virus and extracellular vesicle (EVs*) in vitro and in patients • Two FDA Breakthrough Device designations In advanced/metastatic cancer and life-threatening viruses with no approve
Slide 4: The Aethlon Hemopurifier
The Aethlon Hemopurifi er® • Proprietary, patented technology • 173 treatments administered across 44 patients with a favorable safety profile1 • Has demonstrated the removal of life- threatening enveloped viruses • Designed to clear tumor-derived EVs, and their associated cargo (oncology) 1 Aethlon c
Slide 5: Unique Mechanism of Action
Unique Mechanism of Action How It Works: 1. Plasma Separation: Blood is filtered to isolate plasma (no plasmapheresis required) 2. Size exclusion: Keeps larger, unwanted particles within the lumen of the device while smaller targets pass through to the proprietary affinity resin 3. Targeted Binding: Affi
Slide 6: Hemopurifier Platform – Multi-Disease Potential
Hemopurifi er Platform – Multi-Disease Potential Platform Enablers: Manufacturing, regulatory, IP foundation Oncology Australia - 2 Cohorts complete; final cohort enrollment open; FDA Breakthrough Device Life Threatening Viral Infections Preclinical/clinical-readiness; FDA Breakthrough Device Explorat
Slide 7: Oncology
Oncology MEDICAL, INC.
Slide 8: Why the Hemopurifier Targets Tumor-Derived EVs
Why the Hemopurifi er Targets Tumor-Derived EVs Extracellular Vesicles (EVs) including small EVs known as exosomes (50-150nm) are lipid bilayer enclosed nanoparticles released by all cell types including tumor cells EVs are involved in cell-to-cell communication Extracellular Vesicles contain car
Slide 9: Large and Expanding Checkpoint Inhibitor Market
Large and Expanding Checkpoint Inhibitor Market Market Size Potential Hemopurifier Opportunity PD-1/PD-L1 Market ~$74B in 2026 → • Targets the 60–70% of patients who do not ~$142B by 2031 respond • Approved across multiple tumor types • Novel mechanism: Removes tumor-derived • Increasing use in early
Slide 10: In Vitro Removal Of Cancer-Derived EVs Demonstrated
In Vitro Removal Of Cancer-Derived EVs Demonstrated In Vit ro Experiment s (Miniat ure Hemopurifi er): • Multiple Tumor Types – Removed 92-99% of buffer suspended EVs (Marleau AM, Jacobs MT, Gruber N, et al. Cancer Res 2020;80 (16_Supplement):4509.) • Patient Plasma – Removed EVs directly from plasma
Slide 11: In Vivo Reduction of Exosomes in Head & Neck Cancer
In Vivo Reduction of Exosomes in Head & Neck Cancer Single subject with head and neck cancer following 2 distinct Hemopurifier treatments The total nanoparticle counts decreased following each of the treatments. Slowly rose 7 days following the treatment to levels that were below the baseline mea
Slide 12: Progress in Australian Hemopurifier Oncology Trial
Progress in Australian Hemopurifi er® Oncology Trial Trial Design: Safety, feasibility, and dose-finding study in patients with stable or progressive malignancies while on pembrolizumab or nivolumab. Sequential cohorts receive 1, 2, 3 Hemopurifier treatments over one-week. ANZCTR Link Trial Status Safe
Slide 13: Virology
Virology MEDICAL, INC.
Slide 14: Hemopurifier for Emerging Viral Threats
Hemopurifi er® for Emerging Viral Threats We believe the Aethlon Hemopurifier® is Uniquely Positioned as a Potential Early Treatment Option for Pandemic Threats The next biological attack or pandemic is likely to occur with an enveloped virus Enveloped viruses contain mannose structures that are t
Slide 15: In Vitro and In Vivo Removal of Enveloped Viruses
In Vitro and In Vivo Removal of Enveloped Viruses In vitro: In vivo (Human Subjects): • HIV • West Nile Virus • Hepatitis C • Hepatitis C • H5N1 (Bird Flu) • HIV • Ebola • 1918 Spanish Flu • Ebola • Marburg • EBV • SARs-CoV -2 • Dengue • MERS-CoV • Chikungunya • SARs-CoV-2 Spike Protein • SARs-CoV2
Slide 16: Pre-Clinical Research-Long COVID
Pre-Clinical Research-Long COVID Background: • Long COVID is the persistence of symptoms at least 3 months following acute infection with the SARS-CoV-2 virus • Global incidence of Long COVID is estimated to be 400,000,000 with an economic burden of 1 trillion dollars/year (Nat Med 30, 2148–2164 (20
Slide 17: Pre-Clinical- Platelet-Derived Microparticles (MPs)
Pre-Clinical- Platelet-Derived Microparticles (MPs) Background: • Microparticles derived from activated platelets (PD-EVs) are elevated in a myriad of diseases and associated with disease activity: • SLE (Lupus) • Multiple Sclerosis • Rheumatoid • Alzheimer’s Disease Arthritis • Sepsis • Cancer • Ac
Slide 18: Pre-Clinical- Organ Transplantation
Pre-Clinical- Organ Transplantation Background: • Machine Perfusion (MP) following kidney recovery improves outcomes compared to static cold storage • MP is associated with the release of EVs and microRNAs, which are linked to delayed graft function and acute rejection Hypothesis: The Hemopurifier wo
Slide 19: IP Portfolio Overview
IP Portfolio Overview Layered IP estate protecting our platform, blocking competitive approaches, and extending exclusivity across multiple indications and markets Platform Protection • Core patents covering extracorporeal removal of microvesicles & exosomes • Broad protection across U.S., Europe, a
Slide 20: Key Financial Highlights
Key Financial Highlights Cash Position: ~$5.0 million in cash (March 31, 2026) supporting near term operations and clinical development Debt-Free Balance Sheet: No outstanding debt, maintaining financial flexibility Capital Structure: ~2.4 million shares outstanding (June 2026) 20
Slide 21: Contact Information
Contact Information 11555 Sorrento Valley Road, Suite 203 San Diego, California 92121 619.941.0360 Nasdaq: AEMD wwwˌAethlonMedicalˌcom This presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including: whether and when our prod